Physician profile
Daniel Hu
NPI 1205916442
$716.69
in general payments reported to CMS, 2019-2025
12 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2021: $48.64 · 2022: $3.82 · 2023: $113 · 2024: $59.68 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $160.22 | 2023-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Novartis Pharmaceuticals Corporation | $115.32 | 2019 | |
| Rxsight INC | $84.14 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Katena Products, INC. (Dba Corza Medical) | $82.27 | 2019 | |
| Dompe US, INC. | $55.08 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $53.89 | 2019-2025 | |
| Biotissue Holdings INC. | $43.30 | 2021-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $43.21 | 2021-2024 | Tecnis Iol |
| Alcon Vision LLC | $25.77 | 2025 | Rocklatan |
| Regeneron Healthcare Solutions, INC. | $25.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $24.67 | 2025 | Xdemvy |
| Travere Therapeutics, INC. | $3.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.